Cogent Biosciences, Inc.Cogent Biosciences, Inc.Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

No trades
See on Supercharts

COGT fundamentals

Key facts

Market capitalization

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.


Fundamental metrics to determine fair value of the stock

No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins


Dividend yield, history and sustainability

COGT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company